NCT04436458

Niclosamide In Moderate COVID-19

Phase 2, Multicentre, Randomized, Double Blind, 2 Arms Placebo-controlled Study in Adults With Moderate COVID-19 With Gastrointestinal Signs and Symptoms

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Entero Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, multicentre, randomized, double blind, 2 arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms.

Conditions

• COVID

Interventions

Type	Name	Description
DRUG	Niclosamide Oral Tablet	Continued SOC therapy together with niclosamide TID for 14 days
DRUG	Placebo	Continued SOC therapy together with placebo tablets matching niclosamide for 14 days

Timeline

• Start date: 2022-01-20
• Primary completion: 2022-01-20
• Completion: 2022-01-20
• First posted: 2020-06-18
• Last updated: 2022-02-21